FYI, this guy is not a Forbes writer. He is some Schmo who publishes his gripe/story on the Forbes web site. I didn't read his article, but you see on the page it says:
"The author is a Forbes contributor. The opinions expressed are those of the writer."
This is an ongoing deal with Forbes, and probably explains why the article is poorly written- it is basically this dude's blog posted on Forbes.com.
Here is an explanation of the "contributor" model at Forbes:
New rules for BC/BS blue card is also huge. How many labs actually have a contract with all blues plans? Not many I am sure. This is gonna help labcorp,quest and local labs. May actually keep more specimens from crossing state lines.
This site uses cookies to help personalize content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies and terms of service.